Thus, at least in neuroblastomas and cervical carcinomas, GLS2 appears to promoting an opposite phenotype even though it facilitates the similar metabolic effects as those observed in hepatocellular carcinoma cells. The gene discussed is GLS2; the disease is hepatocellular carcinoma.